Skip to main content
. Author manuscript; available in PMC: 2018 Apr 1.
Published in final edited form as: Pharmacol Ther. 2016 Dec 7;172:116–126. doi: 10.1016/j.pharmthera.2016.12.002

Table 2.

Drugs targeting CD38 or CD38 regulated signaling pathways.

Classification Examples Comments
CD38 inhibitors Thiazoloquin(az)olin(on)es
4-amino-8-quinoline
carboxamides
Kuromanin (Flavinoid)
K-rhein (Anthranoid)		 IC50=7nM against human CD38 (Becherer et
al.)
IC50=76nM against human CD38 (Haffner et
al.)
Inhibits CLL chemotaxis, adhesion and in vivo
homing (Kellenberger et al.)
Inhibition of glioma progress in a mouse model
(Blacher et al.)
Monoclonal
antibody		 Daratumumab FDA approved for multiple myeloma.
Stimulates complement-dependent cytoxicity and
antibody-dependent cellular cytotoxicity (de
Weers et al., and Laubach et al.)
cADPR
antagonist		 8-bromo-cADPR Attenuation of sepsis-induced organ damage in
rats (Peng et al.)
NAADP
antagonist		 NED-19 Inhibition of muscarinic receptor-induced
contractions of guinea pig tracheal contraction
(Naylor et al.)